63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details

臨床試験数 : 363 / 薬物数 : 212 - (DrugBank : 43) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 138

diseases per page:

Showing 1 to 10 of 363 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04812483 (ClinicalTrials.gov)	May 2022	1/3/2021	Immunomodulation With Eltrombopag in ITP	Immunomodulation in Young Adults With Newly Diagnosed Primary Immune Thrombocytopenia(ITP): A Random ...	Primary Immune Thrombocytopenia (ITP)	Drug: Eltrombopag (Revolade®);Drug: standard therapy (without eltrombopag): HD-DXM	University Children's Hospital Basel	Stiftung zur Förderung medizinischer und biologischer Forschung;Novartis Pharmaceuticals;University ...	Recruiting	18 Years	45 Years	All	24	Phase 2	Switzerland
2	ChiCTR2000040991	2022-03-02	2020-12-16	Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a pro ...	Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a pro ...	primary immune thrombocytopenia	experimental group:Cyclosporine A combined with eltrombopag;	The First Affiliated Hospital, College of Medicine, Zhejiang University	NULL	Recruiting	18	75	Both	experimental group:28;	Phase 4	China
3	EUCTR2021-002897-19-HU (EUCTR)	02/03/2022	23/12/2021	A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 in adult participants with Immune thro ...	AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY O ...	Primary immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10083843;Term: P ...	Product Name: PF-06835375 Product Code: PF-06835375 INN or Proposed INN: not available Other descriptiv ...	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	United States;Czechia;Hungary;Canada;Poland;Australia
4	NCT05232149 (ClinicalTrials.gov)	February 2022	20/12/2021	A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocy ...	A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orel ...	Primary Immune Thrombocytopenia	Drug: Orelabrutinib ( lower dose);Drug: Orelabrutinib ( higher dose)	Beijing InnoCare Pharma Tech Co., Ltd.	NULL	Not yet recruiting	18 Years	80 Years	All	30	Phase 2	China
5	NCT05070845 (ClinicalTrials.gov)	January 31, 2022	27/9/2021	Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia	AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY O ...	Primary Immune Thrombocytopenia	Biological: PF-06835375	Pfizer	NULL	Not yet recruiting	18 Years	70 Years	All	40	Phase 2	United States;Poland
6	EUCTR2020-004032-21-DK (EUCTR)	11/01/2022	16/04/2021	A Phase 3 study to evaluate the efficacy and safety of efgartigimod PH 20 Subcutaneous in adult pati ...	A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficac ...	Primary immune thrombocytopenia(ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;Te ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
7	NCT04812925 (ClinicalTrials.gov)	November 17, 2021	15/3/2021	A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patie ...	A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigi ...	Primary Immune Thrombocytopenia	Biological: efgartigimod PH20 SC	argenx	NULL	Recruiting	18 Years	N/A	All	156	Phase 3	United States;Australia;Japan;Russian Federation
8	NCT03692754 (ClinicalTrials.gov)	November 1, 2021	29/9/2018	Atorvastatin in Management of Newly Diagnosed ITP	A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Pri ...	Immune Thrombocytopenia;Purpura, Thrombocytopenic	Drug: Atorvastatin 20mg;Drug: Atorvastatin 10mg;Drug: Dexamethasone	Shandong University	NULL	Not yet recruiting	18 Years	80 Years	All	30	Phase 2/Phase 3	China
9	NCT05029635 (ClinicalTrials.gov)	October 1, 2021	8/8/2021	Phase III Study on HMPL-523 for Treatment of ITP	A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and ...	Immune Thrombocytopenia (ITP)	Drug: HMPL-523;Drug: Placebo	Hutchison Medipharma Limited	NULL	Not yet recruiting	18 Years	75 Years	All	177	Phase 3	NULL
10	NCT05220878 (ClinicalTrials.gov)	September 9, 2021	21/1/2022	Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With Chronic ITP ...	Multicenter Randomized Double-blind Comparative Study of Clinical Efficacy and Safety of GNR-069 (JS ...	Idiopathic Thrombocytopenic Purpura	Biological: GNR-069;Biological: Nplate	AO GENERIUM	NULL	Recruiting	18 Years	75 Years	All	160	Phase 3	Russian Federation

First Previous1 2 3 4 5…37Next Last